Enovix Corporation (ENVX) Income Statement

The erratic growth pattern, including a sequential decline from $11.3M in 2025Q4 to $7.6M in 2026Q1, indicates that revenue is likely driven by lumpy project milestones and NRE payments rather than a smooth, recurring volume ramp. This volatility underscores the company's pre-commercial stage, where individual customer qualification events can cause significant quarterly swings. The durability of growth is therefore questionable until a consistent, high-volume supply model is established.

The recent positive gross margin of 14.4% in 2026Q2 is a notable improvement but appears anomalous compared to the preceding quarters of severe negative margins. This suggests the company may have recognized a specific high-margin NRE payment or benefited from a favorable product mix in that quarter, rather than achieving a sustainable structural shift. The underlying cost structure remains a critical risk, as the business must achieve significant volume to absorb its fixed manufacturing costs.

There is no evidence of positive operating leverage yet; operating income has not scaled with revenue because the cost base is dominated by non-variable R&D and SG&A, which have remained in the $45M-$55M quarterly range. The company's operating margin of -554.83% TTM reflects a business where overhead is orders of magnitude larger than its current revenue base. Achieving operating leverage is entirely contingent on a massive revenue ramp to cover these fixed costs.

The sustained high level of R&D spend, even as revenue has grown, indicates that the company is still in an intensive development phase for its manufacturing processes and next-generation products. This spending level is necessary for its technology moat but is the primary driver of the deep operating losses. Management's ability to control this expense line as it approaches commercialization will be a key indicator of future profitability.